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ABSTRACT
Background Statins are recommended for the secondary prevention of cardiovascular disease, although they are often used in suboptimal doses and 
some patients may not receive lipid-lowering therapy. The Primary Care Data Quality (PCDQ) programme is an audit-based educational intervention.
Objective To report the PCDQ programme’s effect on the cholesterol management in cardiovascular disease.
Subjects and methods Anonymized general practice data from 99 practices; 5% (n = 29 915) had cardiovascular diagnoses.
Results Mean cholesterol fell from 4.75 to 4.64 mmol l−1; patients achieving cholesterol target (< 5 mmol l−1) rose from 45.3 to 53.2%. Coronary 
heart disease patients achieved better control (mean 4.57 mmol l−1) than those with stroke (4.87 mmol l−1) or peripheral vascular disease (4.93 mmol l−1). 
Statin prescribing increased from 57.5 to 62.7%. Patients with diabetes [odds ratio (OR) 2.06, 95% confidence interval (95% CI) 1.91–2.21], prior 
myocardial infarction (MI) (OR 1.93, 95% CI 1.80–2.07), revascularization (OR 1.52, 95% CI 1.33–1.73) and smokers (OR 1.31, 95% CI 1.23–1.39) were 
more likely to receive statins, whereas people aged 75+ (OR 0.48, 95% CI 0.45–0.50), females (OR 0.90, 95% CI 0.86–0.94) and non-CHD-diagnosed 
(OR 0.36, 95% CI 0.34–0.38) were less likely.
Conclusions Diagnostic coding and number of patients who had their cholesterol measured and treated increased. There was no significant 
change in dosage used or inequity between the different groups prescribed statins.
Keywords cardiovascular diseases, cholesterol, computerized statins, family practices, HMG-CoA, medical records system, myocardial ischemia
Introduction
Lowering cholesterol using statin therapy reduces cardiovas-
cular risk, particularly in people with pre-existing ischaemic
heart disease. Consequently, guidelines for secondary
prevention in coronary heart disease, stroke and peripheral
vascular disease recommend cholesterol lowering in patients
with cardiovascular disease. In the United Kingdom, the tar-
get is to reduce total cholesterol to <5mmoll−1. This guid-
ance was first issued in the National Service Framework for
Coronary Heart Disease (NSF CHD) in 20001 and subsequently
reinforced in financially incentivized quality targets in the
new 2005 contract for general practice which was included as
Quality and Outcomes Framework (QOF).2 The value of lower-
ing cholesterol with statins in people with ischaemic heart
disease is well established in a range of large, well-designed,
randomized controlled trials.3–6 The lipid-lowering effect
seen with statin therapy is dose related,7 and the majority of
the statin efficacy studies3–6 have used medium or high doses
of statin.8,9 Statins also have a role in stroke prevention in
that they reduce stroke in those with ischaemic heart
disease.10 The effect does not appear to be related to total
cholesterol levels, because those with a cholesterol level
<5mmoll−1 also benefit from statin therapy.11,12 Peripheral
vascular disease is an arterial disease whose management
benefits from tight cholesterol control.1,13 Some groups
notably the elderly (aged over 75 years),14 females and smok-
ers are less likely to be offered treatment, whereas others
with acute myocardial infarction (MI) and revascularization
are more likely to receive therapy.15,16
The Primary Care Data Quality (PCDQ) programme is an
audit-based educational intervention.17 PCDQ uses the feed-
back of routinely collected computer data to improve data
quality and the quality of chronic disease management.18,19
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The programme is deployed in clinical areas where there is a
strong evidence base for an intervention, ideally, supported
by National guidance, and where there is scope for change
which can be implemented in primary care. Wherever possi-
ble, the programme is locally led, with PCDQ providing the
technical expertise and an educational framework.20
This study set out to determine the impact of a quality
improvement programme on cholesterol management in
people with cardiovascular disease including identifying
which patients receive which statin at what dose.
Method
From the participating practice perspective, the PCDQ pro-
gramme consists of three steps: (i) baseline data collection,
with feedback of data in an educational context; (ii) practices
encouraged to develop local plans to address any quality
issues identified; and (iii) a second data collection, to com-
plete the audit cycle. The educational element consists of
locality meetings at which comparative data are presented to
representatives of participating practices—provision of writ-
ten data summaries comparing the quality of care between
practices, as represented by a practice’s computer records; we
leave in each practice a list of patients who may require fur-
ther review or intervention. With the permission of the prac-
tices, summary data are provided to the clinical lead in the
local primary care organization.
Underpinning the programme is a sophisticated, but
standardized methodology that enables us to consistently
process data from different brands of GP computer system.
We developed audit criteria and defined a data set to provide
feedback on cholesterol management to practices as well as
enabling us to report the effectiveness of the intervention.
We take into account how these clinical concepts, especially
diagnostic data,21 are likely to be coded by GPs, practice
nurses and other practice staff. Morbidity Information Query
and Export Syntax (MIQUEST), a Department of Health
sponsored data extraction tool, was then used to extract data.
Our first data extraction was from two pilot practices. This
pilot output was then presented to the study group, and
modifications were made to the MIQUEST data extraction
queries; the final data set is summarized in Table 1.
Codes were identified which are used in primary care to
categorize people with cardiovascular disease. A broad defi-
nition of cardiovascular disease was used, as defined in the
NSF CHD audit criteria, including cerebrovascular and
peripheral arterial disease. Data were also collected for the
individual component diseases: coronary heart disease,
stroke (which for the purpose of this analysis includes people
with transient ischaemic attacks) and peripheral vascular
disease. Only cholesterol levels recorded within the previous
15 months (the standard set by the QOF2) were included in
the analysis. Approximately 6 months later, following feed-
back and initiation of practice plans, a second data collection
was made. Data were processed using a five-step procedure22
derived from an error reduction approach proposed by
Berndt etal.23 These stages are (i) migration of the data into a
data repository, in this case an My-SQL relational database;
(ii) integration of the data with data from other practices; (iii)
data cleaning; (iv) data processing; and (v) transfer of data
into an appropriate statistical package for analysis. Data were
analysed using SPSS (Statistical Package for Social Sciences)
Version 12.
For the purposes of this analysis, the following data items
were compared across the two data collections: (i) rate of
recording of cardiovascular disease diagnoses including dia-
betes, standardized24 using the 2001 Census population for
England and Wales;25 (ii) total cholesterol, including propor-
tion of patients reaching the UK National target (<5mmoll−1);
(iii) statin use (preparation and dose); and (iv) any change in
demographics or subgroup of patients more or less likely to
receive statins.
We record the ‘flux’ within the population denominator
and index conditions to make any differences between the
before and after populations transparent. We note the
percentage change in the denominator and in the index
conditions—in this study, ischaemic heart disease, cerebrov-
ascular and peripheral vascular disease.
Statistical methods
Mean, standard deviation and standard error were used to
describe normally distributed variables; non-parametric vari-
ables were described using both median and interquartile
range and log-transformed geometric means and standard
deviation. Independent sample t-tests were used to compare
normally distributed continuous variables; Pearson’s chi-square
test was used to test whether the proportions achieving treat-
ment targets on or off therapy were significantly different.
Logistic regression was used to characterize patients on and
off statin therapy, according to a range of categorical varia-
bles. The Wald test was used to test significance.26
Results
The study population was taken from a registered practice
population of 594059 people registered for both data collec-
tions at the 99 participating practices. The interval between
data collections was ∼8 months, longer than the intended 6
months. The mean number of days between collections was
243 days (standard deviation 69.7 days). The demographic
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profile of this study group differed slightly from that of the
UK population, in that adults aged 30–49, especially men, were
over-represented in the sample, whereas children <5 years old
and people aged 60–79 years were under-represented.
Before the intervention, 29094 individuals were identified
with one or more cardiovascular diagnoses. After the inter-
vention, this had risen by 3%, to 29915—55.5% were male
(16588) and 44.5% were female (13327). Mean age for men
was 68.3 years (standard deviation 11.9, standard error 0.092)
and 72.4 years for women (standard deviation 12.9, standard
error 0.078). The excess of younger people will reduce the
apparent prevalence of coronary heart disease; hence, these
results have been adjusted using the 2001 Census population
for England age profile (Table 2). The age-adjusted prevalence
Table 1 Variables included in the Primary Care Data Quality (PCDQ) cardiovascular programme
Patient identifiers + multiple sclerosis as data quality indictor
1. MIQUEST unique ID
2. YoB (year of birth)
3. Sex
4. First part Post Code (to link to socioeconomic data)
5. Ethnicity (very poor levels of recording)
6. MS code (multiple sclerosis is used as data quality index)
7. Usual doctor code, to identify patterns between professionals
Read coded variables
1. Systolic BP (latest, value, + date recorded)
2. Diastolic BP (latest, value, + date recorded)
3. Height and weight (latest)
4. Smoking (smoking habit data Y/N + date given of last code)
a. Smoking code that implies current smoker (+ date given)
b. Smoking code that implies non-smoker/ex-smoker
c. Smoking code NEVER smoked (+ date recorded)
d. Advice to stop smoking given to members of groups A + B above (Y/N + date given)
5. Cholesterol and lipids
a. Total cholesterol (most recent, no mg, date recorded)
b. LDL (most recent, mmoll−1, date recorded)
c. HDL (most recent, mmoll−1, date recorded)
d. TGs (most recent, mmoll−1, date recorded)
e. TC/HDL ratio (most recent, value, date recorded)
f. We may need earliest available cholesterol and LDL and date
g. Date when first diagnosed ‘Hyperlipidaemia’
h. Weight at time of diagnosis
i. Date first prescribed a lipid-lowering agent and first agent
j. Advice to adjust diet given to members of groups A + B above (Y/N + date given)
6. Diabetes mellitus
a. Diagnosis codes
b. Blood glucose (most recent, mmoll−1, date recorded)
c. HbA1c (glycosylated haemoglobin most recent, date recorded)
d. Insulin dependence and date first prescribed if available
e. Date diagnosis made of diabetes mellitus
f. Weight at the time of diagnosis
g. Advice to adjust diet given to members of groups A + B above (Y/N + date given)
7. Hypertension and date diagnosis made
8. Last two lipid-lowering drug prescriptions issued (exact preparation including dose, number of tablets and date issued)
9. Statin monitoring and side effects proxy
a. Transaminase (most recent, value, date)
b. CPK (most recent, value, date)
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for ischaemic heart disease is 4.03% (male 4.64%, female
3.40%), 1.86% for stroke/transient ischaemic attack (male
1.82%, female 1.90%), and 0.70% for peripheral vascular dis-
ease (male 0.83%, female 0.56%). Over the study period, the
population registered with the study practices declined by
5.7% (34270); the proportions of leavers who had cardiovas-
cular disease were similar to those in the study population as
a whole: ischaemic heart disease 3.9%, stroke/transient
ischaemic attack 2.1% and peripheral vascular disease 0.75%.
Cardiovascular disease comorbidity was observed in
14.2% of patients: 3863 (12.9%) had two diagnoses recorded
and 396 (1.3%) had three. Comorbid patients were more
likely to be older (men: mean age 72.2 years, median 73.3 and
women: mean age 76.2 years, median 78.1): 28.2% of men
and 15.8% of women in the sample had a history of acute
MI; 18.4% of men and 14.9% of women had diabetes; 7.2%
of men and 2.9% of women had undergone a coronary
revascularization procedure; 25.4% of men and 21.7% of
women were recorded as current or ex-smokers.
Pre-intervention, a recent cholesterol record (defined as
within 15 months in the UK general practice contract) existed
for 76.3% of patients. The arithmetic mean cholesterol was
4.86mmoll−1 [95% confidence interval (95% CI) 4.85–4.88];
geometric mean was 4.75mmoll−1 (95% CI 4.74–4.76). Given
that cholesterol levels have a non-normal distribution (data
not shown), a geometric mean is preferred to give a more
meaningful result. Within the cardiovascular disease popula-
tion, 45.3% achieved the target cholesterol of <5mmoll−1.
There was a significant variation within this group, more of
those on a statin (61.4%) achieved target, compared with
23.5% of those not taking a statin (chi-square, P < 0.001).
There were also significant differences between patients with
the three index diseases (Table3). People with CHD tended
to have better control of cholesterol than those with stroke
or peripheral vascular disease. Low-density lipoprotein cho-
lesterol (LDL-C) was only recorded for 59% of people with
cardiovascular disease overall, and there were quite marked
interpractice variation in recording: median recording level
47%, interquartile range 19.2–68.1%.
Following the initial data collection and feedback process,
a second data collection was performed. A greater propor-
tion had their cholesterol measured (83.1%) (Table3) and
reached target (53.2%): 10% more patients with ischaemic
heart disease and stroke and 7% of patients with peripheral
Table 2 Prevalence of coronary heart disease, stroke and transient ischaemic attack and peripheral vascular disease in the study sample
Number of cases Age-adjusted prevalence
Total Male Female Total (%) Male (%) Female (%)
Coronary heart disease
0–24 27 19 8 0.02 0.02 0.01
25–44 359 247 112 0.19 0.24 0.13
45–64 5806 3995 1811 4.39 5.81 2.85
65–84 12801 7244 5557 19.16 24.54 14.81
85+ 2029 703 1326 24.12 28.47 21.86
All 21022 12208 8814 4.03 4.64 3.40
Stroke/transient ischaemic attack
0–24 73 35 38 0.05 0.05 0.05
25–44 398 126 272 0.21 0.12 0.31
45–64 2128 1182 946 1.61 1.72 1.49
65–84 5761 2978 2783 8.63 10.09 7.42
85+ 1348 431 917 16.02 17.46 15.12
All 9708 4752 4956 1.86 1.82 1.90
Peripheral vascular disease
0–24 10 3 7 0.01 0.00 0.01
25–44 98 45 53 0.05 0.04 0.06
45–64 799 515 284 0.60 0.75 0.45
65–84 2350 1431 919 3.52 4.85 2.45
85+ 360 157 203 4.28 6.36 3.35
All 3617 2151 1466 0.70 0.83 0.56
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vascular disease reached targets. The mean cholesterol was
lowered to 4.64mmoll−1 (arithmetic mean 4.75 mmoll−1).
As with the pre-intervention results, people with ischae-
mic heart disease appeared to be managed much more
aggressively than those with stroke or peripheral vascular dis-
ease: 88.9% of those with ischaemic heart disease had had a
recent cholesterol reading; mean total cholesterol was
4.67mmoll−1 and 60.1% achieved treatment goal. In contrast,
only 69.2% of stroke patients without co-existing ischaemic
heart disease had a cholesterol reading recorded. The mean
cholesterol of those with a recording in stroke was
4.98mmoll−1 and 37.1% of the population reached target.
The proportions were similar in peripheral vascular disease.
Before the PCDQ intervention, 57.5% of the patients with
cardiovascular disease were taking a statin, which rose to
62.7% in the second data collection. Despite this increase in
overall prescription of statins, the pattern of prescribing
remained little changed, in terms of both agents used and the
mean dose of each agent. Post-intervention, the mean dose
of simvastatin was 24.3mg with more than 20% of patients
receiving 10mg. Almost 60% of pravastatin patients were
prescribed 40mg, whereas the remainder received 10 or
20mg (Table 4). Although 95.3% (n = 17858) of prescrip-
tions for lipid-lowering drugs were for statins, other agents
were used. Ezetimibe accounted for 2.4% (n = 443); fibrates for
1.5% (n = 342); fish oils, anion exchange resins and nicotinic
acid were used rarely (n = 48, n = 31 and n = 19, respectively).
Patients with total cholesterol >5mmoll−1 not treated with
statins are unlikely to reach target. In the ischaemic heart dis-
ease population, only 53.1% (n = 15871) had a total choles-
terol <5mmoll−1, either as a result of statin treatment
(78.7%) or because this is their natural untreated level
(21.3%). In 42.8 of the 46.9% who failed to reach target, this
reflected inadequate dosing of lipid-lowering therapy,
whereas the remainder (57.2%) were on no treatment at all.
Although the absolute proportion of those reaching target
varies according to the precise diagnosis, the underlying
trend remains the same (data not shown).
Logistic regression was used to explore the factors that
predict a failure to prescribe statins to people with a total
cholesterol level of ≥5mmoll−1 (Table 5). Those with non-
ischaemic heart disease, cardiovascular disease, stroke or
peripheral vascular disease were less likely to be treated with
a statin compared with people with ischaemic heart disease.
Those aged 75 or over and women were significantly less
likely to be treated [odds ratios (OR) 0.48 and 0.90, respec-
tively]. People with uncontrolled hypertension (defined as
blood pressure of >160/95mmHg, n = 685, 2.3% of CHD
population) were significantly less likely to be on statins.
However, patients with diabetes were significantly more
likely to be treated (OR 2.06), as were smokers and ex-smokers
and those who had undergone revascularization procedures.
Post-intervention data show that there was no significant dif-
ference between pre- and post-intervention.
Discussion
Main findings of this study
More patients with cardiovascular disease have been identi-
fied in primary care. Good progress has been made towards
treatment targets in ischaemic heart disease, with 60% of the
population with a total cholesterol of <5mmoll−1. A greater
proportion have their cholesterol measured and are being
treated, largely with statins. However, about one-third of
patients treated with a statin fail to reach the <5mmoll−1 cho-
lesterol target. More than one-half of patients with cerebrov-
ascular or peripheral vascular disease continue to have a total
cholesterol of >5mmoll−1and one-half are not taking a statin.
Table 4 Patterns of statin use before and after Primary Care Data Quality (PCDQ) intervention
Patients taking a statin 
both pre- and post-intervention
Patients taking a statin 
as a result of the intervention
Pre-PCDQ Post-PCDQ n % Mean dose (mg)
n % Mean dose (mg) n % Mean dose (mg)
Atorvastatin 5909 35.7 19.6 6081 36.8 20.8 657 33.8 17.9
Fluvastatin 327 2.0 37.5 298 1.8 38.6 20 1.0 39.0
Pravastatin 2090 12.6 29.6 1956 11.8 30.1 110 5.7 33.5
Rosuvastatin 787 4.8 13.7 861 5.2 13.6 99 5.1 11.1
Simvastatin 7427 44.9 24.6 7344 44.4 25.6 1055 54.4 27.0
Any statin 16540 16540 1941
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Where statins are being used, they tend to be prescribed at
low doses and only a small proportion of patients have their
dose increased, changed to a more potent statin or have
other lipid-lowering agents added. There are a number of
identifiable factors that determine the likelihood of an indi-
vidual receiving a statin. Patients with diabetes, a past history
of acute MI or coronary revascularization and smokers or ex-
smokers were more likely to be treated. Conversely, treat-
ment was less likely in women, those aged over 75 and
patients with stroke, transient ischaemic attack or peripheral
vascular disease as their index event. In addition, patients
with a most recently recorded blood pressure >160/
95mmHg were less likely to receive statin treatment. How-
ever, this is a small proportion of patients with cardiovascu-
lar disease (2.3%) and may represent those in the process of
treatment adjustment.
What is already known on this topic
The prevalence of diseases included in the QOF was published
in June 2005. The prevalence of ischaemic heart disease was
3.46–4.27%.27 The age-adjusted figure of 4.03% found in the
present study fits within this range. For stroke, our prevalence
of 1.86% falls well above the UK range of 1.33–1.76%.
Although this difference appears small, on a population of the
size of our sample (almost 600000), it represents a difference
of between 550 and 1760 patients. One likely explanation for
this discrepancy is the relatively limited range of Read codes
used to define cerebrovascular disease included in QOF. In
the present study, all possible codes were included. This phe-
nomenon may help explain why there is a cohort of under-
treated patients with non-ischaemic heart disease diagnoses.28
With computerized decision support only identifying QOF-
qualifying patients, it is not surprising that the broader second-
ary prevention falls short in this subset.
The data fit with other studies, which have shown subop-
timal control of abnormal lipid profiles post-MI29 and in
people with stroke.30 They also correspond with previous
findings that older people and women are less likely to be
prescribed statins, whereas those with MI and revasculariza-
tion are more likely.14–16 Our finding that smokers were
more likely to be prescribed statin treatment, however, is at
variance with other published data. This may reflect that we
pooled both current and ex-smokers in our analysis, whereas
others have examined current smoking status only. Our data
regarding the suboptimal dosing of statins are consistent
with the pattern seen elsewhere.31,32 It may be that data
which cast doubt on the value of intensive statin therapy
reinforce the use of low-dose therapy33—a similar phenome-
non is seen in the management of heart failure.34,35
What this study adds
To achieve all the relevant quality points and receive
maximum quality-related pay, practices have to record
cholesterol within the last 15 months in 90% of patients
and 60% of patients with cardiovascular disease must have
total cholesterol of <5mmoll−1.2 These data show that par-
ticipating practices reached the highest quality standard
half-way through the first year of the new GP contract.
However, behind the quality points, there is considerable
unmet need.
Certain groups appear less likely to receive statins. The
association between female sex and the likelihood of statin
treatment is small (OR 0.90) but highly significant (95% CI
0.86–0.95; P < 0.0001). It is possible that this reflects a con-
founding factor that has not been taken into account in our
model. The evidence for discrimination against the elderly (aged
over 75 years) is less equivocal (OR 0.48, 95% CI 0.45–0.50,
P < 0.00001) and reflects a genuine dilemma. On the one
Table 5 Factors influencing likelihood of treatment with statins: logistic regression analysis
Chi-square statistic = 4062.3224, P < 0.00001.
Likelihood ratio = 4272.7503, P < 0.00001.
Risk factor Odds ratio 95% CI Coefficient SE Z P-value
Diabetes 2.06 1.92–2.21 0.7214 0.0362 19.91 <0.00001
Acute myocardial infarction 1.93 1.80–2.07 0.6585 0.0362 18.17 <0.00001
Revascularization 1.52 1.33–1.73 0.4165 0.0665 6.26 <0.00001
Smoker or ex-smoker 1.31 1.23–1.39 0.2711 0.0315 8.61 <0.00001
Female sex 0.90 0.86–0.95 −0.1043 0.0264 −3.95 <0.0001
Raised blood pressure (>160/95) 0.79 0.67–0.94 −0.2300 0.0837 −2.75 <0.01
Aged 75+ 0.48 0.45–0.50 −0.7426 0.0265 −28.03 <0.00001
Non-ischaemic heart disease index event 0.36 0.34–0.38 −1.0188 0.0290 −35.13 <0.00001
Constant 0.8809 0.0273
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hand, no randomized control trials of statin therapy have
studied patients beyond their early 80s, and in one study,
there was a suggestion of tailing-off of effect in the older age
group.36 On the other hand, meta-analysis of all statin studies
shows a remarkable degree of homogeneity between treat-
ment groups,37 with some evidence for enhanced treatment
benefit amongst the very elderly.38 It is difficult to justify this
apparent bias against secondary prevention patients aged
>75 years.
Limitations of the study
There is no evidence that the PCDQ intervention resulted
in the changes reported. Financial incentives within the
QOF may have been much more important. However, a
cynical approach to purely increase QOF points would be
directed towards achieving monitoring and control in
people with an existing diagnosis, rather than finding new
cases. The intervention failed to encourage the use of
higher doses of statins or greater equity in the use of
statins.
The study may under-report the quality of care; computer-
generated searches of data can also miss patients.39–41 Some
patients may have been found to have an elevated cholesterol
level and initiated on statin therapy; their improved choles-
terol will not as yet have been recorded. We only reported
structured or Read coded data. It is not possible to extract
narrative or free text data in a format that can be analysed
readily. Therefore, if cholesterol and other data were con-
tained in letters or written in text, it would not be included in
the study.
We did not report LDL-C because, although we
extracted the data, recordings were variable and some labo-
ratories routinely report HDL-C and HDL-C/total choles-
terol ratio rather than LDL-C. We were unable to identify
individuals who had satisfied NSF criteria by achieving a reduc-
tion of 30% or more, while still retaining post-intervention
cholesterol of >5mmoll−1, as there was no reliable way of
ascertaining pre-treatment cholesterol levels from the
PCDQ database. However, it is likely that the numbers in
this category were small, as to remain above the 5mmoll−1
target would have required a pre-treatment level of
>7.15mmoll−1. Data derived from a previously published
study would suggest that fewer than 5% of untreated CHD
patients in the United Kingdom would potentially fulfil this
criterion.17
Call for further research
We need to understand the rationale for prescribing low-
dose statins to patients not achieving current cholesterol
targets. The failure to increase dose, switch statin or add
another lipid-lowering agent for these patients is difficult to
understand.
Conclusions
Practitioners have improved cholesterol management across
the population with cardiovascular disease; however, much
remains to be done to improve the management of choles-
terol in people with stroke/transient ischaemic attack and
peripheral vascular disease. Practitioners who achieve maxi-
mum quality points may feel that they have achieved the
highest possible standard of cholesterol management and be
unaware of the unmet need. There is scope to tighten quality
targets, either by lowering the cholesterol target or by
increasing the proportion of patients that should achieve it.
More needs to be done to improve the basics of cholesterol
management in coronary heart disease; we need to fill the
gaps in statin prescribing and reduce the use of suboptimal
doses.
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